GZ402665
Drug
GENZYME CORPORATION
Total Payments
$1.8M
Transactions
485
Doctors
8
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1.5M | 62 | 3 |
| 2018 | $103,308 | 219 | 7 |
| 2017 | $164,825 | 204 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 428 | 97.2% |
| Consulting Fee | $49,054 | 54 | 2.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,265 | 3 | 0.1% |
Payments by Type
Research
$1.7M
428 transactions
General
$50,319
57 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Olipudase Alfa in Patients With Ac | GENZYME CORPORATION | $803,876 | 0 |
| A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency | GENZYME CORPORATION | $578,920 | 0 |
| A Phase 1/2, Multi-Center, Open-Label, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Olipudase Alfa in Pediatric Patients Ag | GENZYME CORPORATION | $215,700 | 0 |
| A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Olipudase Alfa in Patients With Ac | SANOFI US SERVICES INC. | $100,559 | 0 |
| A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency | SANOFI US SERVICES INC. | $15,855 | 0 |
| A Phase 1/2, Multi-Center, Open-Label, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Olipudase Alfa in Pediatric Patients Ag | SANOFI US SERVICES INC. | $13,049 | 0 |
| Prospective, Cross-Sectional Survey Study to Collect Natural History Data in Patients with Niemann-Pick B Disease | GENZYME CORPORATION | $795.00 | 2 |
| A phase 1-2, multi-center, open-label, ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of recombinant human acid sphingomyelinase | GENZYME CORPORATION | $318.00 | 1 |
Top Doctors Receiving Payments for GZ402665
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Sacramento, CA | $1.7M | 422 |
| , MD | Anesthesiology | Boston, MA | $17,200 | 17 |
| , MD | Internal Medicine | Boston, MA | $16,571 | 26 |
| , MD | Internal Medicine | Birmingham, AL | $9,280 | 6 |
| , MD | Pediatrics | Boston, MA | $6,003 | 5 |
| , MD, PHD | Clinical Genetics (M.D.) | Stony Brook, NY | $819.24 | 3 |
| , MD | Clinical Genetics (M.D.) | New York, NY | $819.24 | 3 |
| , MBBS PHD | Gastroenterology | New Haven, CT | $421.74 | 1 |
| , M.D., PH.D | Pediatrics | New York, NY | $318.00 | 2 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $1.6M
- SANOFI US SERVICES INC. $129,463
- SANOFI-AVENTIS U.S. LLC $49,054
Product Information
- Type Drug
- Total Payments $1.8M
- Total Doctors 8
- Transactions 485
About GZ402665
GZ402665 is a drug associated with $1.8M in payments to 8 healthcare providers, recorded across 485 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2019. In 2019, $1.5M was paid across 62 transactions to 3 doctors.
The most common payment nature for GZ402665 is "Unspecified" ($1.7M, 97.2% of total).
GZ402665 is associated with 8 research studies, including "A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Olipudase Alfa in Patients With Ac" ($803,876).